Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.36 and traded as low as $0.15. Eagle Pharmaceuticals shares last traded at $0.15, with a volume of 205 shares.
Eagle Pharmaceuticals Trading Down 23.1%
The stock has a market cap of $1.95 million, a PE ratio of 0.13 and a beta of 0.83. The business has a fifty day simple moving average of $0.38 and a two-hundred day simple moving average of $1.36.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Woodcliff Lake, New Jersey, that focuses on the development, manufacturing and commercialization of hospital-administered therapies in the areas of critical care, oncology and rare diseases. Founded in 2007, Eagle has built expertise in complex injectable formulations and orphan drug designation, aiming to address unmet medical needs through both novel products and reformulated generics.
The company’s marketed portfolio in the United States includes Bendeka®, an intravenous formulation of bendamustine for certain types of leukemia and lymphoma; Beleodaq®, approved for relapsed or refractory peripheral T-cell lymphoma; and Empaveli®, a complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
Further Reading
- Five stocks we like better than Eagle Pharmaceuticals
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- Unlocked: Elon Musk’s Next Big IPO
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Read this or regret it forever
- Silver paying 20% dividend. Plus 68% share gains
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
